IGF-1 LR3 (Insulin-Like Growth Factor-1, Long R3)

What it is?

IGF-1 LR3 is a long-acting IGF-1 analogue studied for its role in cell growth, repair signalling, and anabolic pathway activation. Its modified structure is designed to extend activity time compared with native IGF-1.

Dripfy Standard

• Receptor engagement: Binds to IGF-1 receptors (IGF-1R) to initiate anabolic signalling cascades.
• Signal transduction: Supports downstream pathways commonly linked to growth and adaptation, including PI3K/AKT/mTOR and MAPK signalling.
• Protein turnover effects: Shifts cellular signalling toward increased protein synthesis and improved muscle maintenance dynamics.
• Recovery signalling: Associated with myoblast differentiation and repair-related processes following training-induced microdamage.
• Extended bioactivity profile: Modified structure is positioned to reduce binding constraints (e.g., IGF-binding interactions), supporting longer functional activity in research settings.

Clinical Applications & Therapeutic Potential

• Anabolic signalling support: Upregulation of pathways associated with muscle hypertrophy and adaptation via IGF-1R downstream signalling.
• Protein turnover modulation: Increased protein synthesis signalling with a concurrent shift in proteolysis-related markers.
• Regeneration & recovery dynamics: Support for satellite-cell activity and muscle-fibre repair signalling following mechanical stress.
• Performance adaptation markers: Improved tolerance to training load through enhanced recovery kinetics.

Composition & Formulation

• Peptide content: 1 mg IGF-1 LR3
• Vehicle: Proprietary pH-balanced buffer solution
• Delivery system: Pre-filled, multi-dose, closed-system pen
• Total volume: 3 mL
• Purity: ≥99% by HPLC/MS